Core Viewpoint - DBV Technologies plans to change the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective around June 3, 2024 [1][2]. Group 1: ADS Ratio Change - The current ADS Ratio of one ADS to one-half of an ordinary share will change to one ADS to one ordinary share [1]. - This change will be treated as a one-for-two reverse ADS split for ADS holders [2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2][3]. Group 2: Impact on Trading and Compliance - The change is expected to increase DBV's ADS trading price proportionally, although no assurance can be given that the new price will be at least double the previous price [4]. - The ADS Ratio Change will not affect the underlying ordinary shares, and no ordinary shares will be issued or cancelled [3]. Group 3: Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions [5]. - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT) [5]. - DBV is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for its Viaskin Peanut product [5].

No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. The ADS Ratio Change will have no impact on DBV's underlying ordinary shares, and no ordinary shares will be issued or cancelled in con ...

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the "Company"), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel ...

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 1 ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNOLOGIES S.A. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporation ...

Exhibit 99.1 Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May ...

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), will hold its Combined General Meeting (the "General Meeting") on May 16, 2024, a ...

                                                                                                                                                                                                                                                                                                                 Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Marke ...

Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. ...

DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Conference Call March 7, 2024 5:00 PM ET Company Participants Katie Matthews - Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Virginie Boucinha - Chief Financial Officer Conference Call Participants Jon Wolleben - Citizens JMP Sushila Hernandez - Van Lanschot Kempen Operator Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and Business Update Conference C ...